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Mid-term follow-up after heart valve replacement 
with CarboMedics bileaflet prostheses 
To the Editor: 
I read with interest he article by de Luca and associ- 
ates I concerning valve replacement with the CarboMedics 
bileaflet prosthesis, and I commend them for providing 
valuable information to help surgeons evaluate the re- 
cently approved CarboMedics valve (CarboMedics, Inc., 
Austin, Tex.). The authors have carefully adhered to the 
published guidelines for reporting valve-related complica- 
tions 2 in virtually all areas. The completeness of their 
follow-up and the detail of their presentation are admira- 
ble. 
One area of their report has results that appear to be 
misleading, namely, the presentation of linearized rates of 
valve-related complications reported for aortic, mitral, 
and double valve replacement. The presentation of accu- 
rate information is important, because on page 1163 of 
their report the authors state that their incidence of 
thromboembolic complications is low, at 0.5%/pt-yr, com- 
pared with other series. Analysis of the information 
provided in the Results section on page 1160 reveals that 
the linearized rates calculated for the individual events are 
probably erroneous. For example, the authors state on 
page 1160 that thromboembolic events were observed in 
seven patients. If the cumulative patient follow-up was 478 
patient-years, asstated on page 1159, then the linearized 
rate for thromboembolism would be 1.5%/pt-yr, not 0.5%/ 
pt-yr. 
A further difficulty arises when the authors present 
linearized rates segregated according to valve procedure. 
Although they do not provide us with a breakdown of the 
individual events by operative procedure, their report of 
the linearized rates of thromboembolism for aortic 
(0.35%/pt-yr), mitral (0.8%/pt-yr), and double valve re- 
placement (0.3%/pt-yr) cannot be correct. Linearized 
rates for valve-related complications separated according 
to valve operation must be divided by the patient-years of 
follow-up for only that valve operation group to accurately 
represent the linearized rate. The authors appear to have 
generated a "linearized rate" by dividing the percentage 
of patients free of an event actuarially by the follow-up 
interval of 31/2 years. 
Similar computational errors can be found in the pre- 
sentations of valve-related eath, anticoagulant-related 
hemorrhage, nonstructural valvular dysfunction, pros- 
thetic valve endocarditis, and incidence of reoperation. In
terms of sustaining the high quality of their report, I ask 
that de Luca and colleagues generate accurate linearized 
rates for the valve-related complications that they have 
noted for the combined and separate operative proce- 
dures. This information would be valuable for cardiac 
surgeons who are seeking to generate data 3 that allow 
comparison of the various available prostheses, with an 
aim toward finding the most appropriate prostheses for 
their patients. 
Cary W. Akins, MD 
Department of Cardiac Surgery 
Massachusetts General Hospital 
Boston, MA 02114 
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Reply to the Editor: 
We appreciate the opportunity to respond to the com- 
ments of Dr. Akins regarding our article. ~ He gave us the 
benefit of his experience. 2 
With regard to linearized rates of valve-related compli- 
cations, data were analyzed by applying the Mantel- 
Haenszel test included in the program 1L of the BMDP 
statistical software package (BMDP Statistical Software, 
Inc., Los Angeles, Calif.). 3 This test takes into account he 
number of events for a given time divided by the number 
of patients followed up for the same time interval)' 4 In 
our study we assumed a 6-month interval. This type of 
calculation is presented in our article as the curve at the 
bottom of each graph. The combined and separate linear- 
ized rates presented in our report were obtained with this 
test, by summing up the patient-year incidences of each 
time interval divided by the total number of time intervals 
of follow-up)' 4 Moreover, linearized rates of each sub- 
group of patients were calculated including only the 
patients undergoing that operative procedure. For all 
these reasons, they would be better defined as linearized 
incidences than as linearized rates, and we apologize not to 
have mentioned this statistical aspect in our paper. 
On the other hand, linearized rates are generated by the 
number of events divided by the number of patient-years. 
As requested by Dr. Akins, we list the linearized rates of 
our population for the valve-related complications that we 
have noted for the combined and separate operative 
procedures (Table I). The rates were calculated according 
to this latter method. 
We are grateful to Dr. Akins for raising this statistical 
issue of our paper that would have been overlooked 
Table I. Linearized rates of valve-related 
complications 
Total MVR A VR D VR 
Event (%/pt-yr) (%/pt-yr) (%/pt-yr) (%/pt-yr) 
NSD 0.6 - -  0.5 2 
ARH 1 - -  1.5 2 
TE 1.5 2.9 1 - -  
Reoperation 0.6 1.7 - -  - -  
PVE 0.2 - -  0.5 - -  
VRD 1.5 1.2 1.5 2 
ARH, Anticoagulant-related h morrhage; AVR, aortic valve replacement; 
DVR, double (mitral and aortic) valve replacement; MVR, mitral valve 
replacement; NSD, nonstructural dysfunction; PVE, prosthetic valve endo- 
earditis; TE, thromboembolie events; VRD, valve-related eaths. 
